Henry Schein Can Make Your Portfolio Smile

Henry Schein stands out as the largest global provider of healthcare products and services for office-based dental and medical practitioners, with a strong market share. HSIC continues to deliver solid growth, reporting Q3 revenue up 5.2% year-over-year and improved profitability across all segments, driven by internal growth and targeted programs. Management anticipates ongoing revenue and EBITDA growth, supported by demographic trends, increased healthcare access, and technological advancements like AI in dental care.

Seeking Alpha • Dec 5, 2025

Why Is Henry Schein (HSIC) Up 1.2% Since Last Earnings Report?

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 4, 2025

Henry Schein, Inc. (HSIC) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Henry Schein, Inc. (HSIC) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 2, 2025

HSIC Stock Benefits From Expanded Partnership With vVARDIS

Henry Schein gains exclusive U.S. rights to Curodont, expanding its vVARDIS partnership and boosting expectations for a Dental business rebound.

Zacks Investment Research • Dec 2, 2025

HSIC Stock Set to Benefit From Henry Schein One's Workflow Launch

HSIC gains momentum as Henry Schein One rolls out AI-powered dental workflows unveiled at the Greater New York Dental Meeting.

Zacks Investment Research • Dec 1, 2025

Henry Schein Expands Partnership with vVARDIS

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) today announced the expansion of its agreement with vVARDIS, which grants the Company exclusive U.S. distribution rights for the drill-free Curodont™ Repair Fluoride Plus (“Curodont”) product across all dental market segments, effective January 1, 2026. The strategic expansion broadens Henry Schein's previous exclusivity with the Swiss company, which was announced in 2024 for Dental Service Organizations (DSOs). Starting next ye.

Business Wire • Dec 1, 2025

Artisan Select Equity Fund Q3 2025 Portfolio Review

Alphabet shares rose 38% during the quarter. This represents a striking $810 billion increase in market value. Samsung shares rose 36% in the quarter, adding over $100 billion of market value. Samsung shares are finally starting to benefit from AI enthusiasm. Elevance's share price declined by 16%, making it our largest negative contributor.

Seeking Alpha • Nov 27, 2025

Henry Schein One Unveils Industry-first Natively Embedded Voice Workflow at 2025 Greater New York Dental Meeting

AMERICAN FORK, Utah--(BUSINESS WIRE)--Coming off the heels of its announcement with Amazon Web Services, Henry Schein One, the leading provider of global dental technology, today unveils natively embedded AI and automation workflows. This includes Voice Notes, which helps practices close revenue gaps through clean claims, and modernize more effectively. “Our goal isn't piecemeal AI and automation — it's natively embedded AI with a purpose,” said Dr. Ryan Hungate, Chief Clinical and Strategy Off.

Business Wire • Nov 25, 2025

American Century Mid Cap Value Fund Q3 2025 Contributors/Detractors And Notable Trades

Shares of Teradyne advanced sharply as investors cheered the company's robust earnings and outlook for Teradyne's artificial intelligence compute testing business. Shares of Henry Schein declined as promotional activity to attract new customers in its online channel pressured margins. We exited our position in Centene and reallocated proceeds to other positions that we believed offered more attractive risk/reward opportunities.

Seeking Alpha • Nov 20, 2025

Henry Schein, Inc. (HSIC) Presents at Jefferies London Healthcare Conference 2025 Transcript

Henry Schein, Inc. ( HSIC ) Jefferies London Healthcare Conference 2025 November 18, 2025 9:30 AM EST Company Participants Stanley Bergman - Executive Chairman & CEO Andrea Albertini - Chief Executive Officer of Global Distribution & Technology Graham Stanley - VP of Investor Relations & Strategic Finance Project Officer Conference Call Participants Michael Sarcone - Jefferies LLC, Research Division Presentation Michael Sarcone Jefferies LLC, Research Division Hi, everyone. My name is Mike Sarcone.

Seeking Alpha • Nov 18, 2025